Skip to content
Companies

Rejuvenate Bio

Gene therapies for age-related disease in dogs and people

Raised to date

$19.5M

of $27M offered across 1 Form D filing

Still open
$7.6M
Investors
35
Last filed
Jun 18, 2026

About

Rejuvenate Bio develops AAV gene therapies aimed at the underlying biology of aging rather than the symptoms of individual age-related diseases. The company originated from George Church's lab at Harvard and works on cardiac, metabolic and renal indications. It pursues a dual-species strategy, developing therapies for companion animals — dogs with heart disease, osteoarthritis and cancer — alongside a human program. Revenue, safety data and partner funding from the animal health path are intended to carry the platform into human medicine.

Targets the shared root drivers of aging so a single one-time gene therapy can address multiple cardiac, metabolic and renal conditions at once, and de-risks the platform commercially through the faster animal-health regulatory path before human trials.

Funding

  • EquityFiled Jun 18, 2026Form D
    $19.5M/ $27M

Product

RJB-0402

Gene therapy

A liver-directed AAV gene therapy delivering FGF21, listed on the company's pipeline as its human program for metabolic and age-related conditions.

  • Adeno-associated virus (AAV) delivery
  • Liver-directed expression of FGF21
  • One-time administration

Built for

Veterinary clinics and pet owners treating dogs with age-related chronic disease in the near term, with patients and clinicians treating human cardiac, metabolic and renal disease as the longer-term market

People on file